 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
2 News |  |
- | Ranibizumab BS (ranibizumab biosimilar) / Noritsu Koki, Senju
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan. (Pubmed Central) - May 12, 2023
This study suggests that RBZ BS is dominant to other anti-VEGF treatments in patients with nAMD in both TAE and PRN regimens and BSC from a Japanese societal perspective.